Psychedelic research and access in
Tennessee
Tennessee remains a standard controlled-substances jurisdiction for classical psychedelics. Current Tennessee rules list psilocybin and psilocin in Schedule I, and the reviewed materials did not identify an enacted psychedelic-specific access pathway, state service model or local deprioritisation framework.
Key Insights
- 1
Tennessee remains a Schedule I state for psilocybin and psilocin.
- 2
No verified Tennessee pathway was found for state-regulated psilocybin or MDMA treatment.
- 3
Practical access is conventional ketamine/esketamine care, not psychedelic reform.
- 4
Vanderbilt provides a credible ketamine research node, but Tennessee is not yet a verified classical-psychedelic research hub.
- 5
Tennessee should be framed as administratively stable and policy-quiet in this area.
Research Snapshot
Deep reportBlossom currently tracks 9 psychedelic clinical trials with verified sites in Tennessee, including 4 active studies.
- Active trials
- 4
- Total trials
- 9
- Stakeholders
- 8
- Events
- 0
Verified state-linked study sites
Linked trial records
8 physical, 0 jurisdiction-linked
Linked state-level events
Top Compounds
- Esketamine(2)
- Ketamine(2)
- LSD(2)
- MDMA(2)
- Psilocybin(1)
Top Study Topics
- Major Depressive Disorder (MDD)(4)
- Healthy Volunteers(2)
- Anxiety Disorders(1)
- Autism Spectrum Disorder (ASD)(1)
- PTSD(1)
Active Trial Preview
View linked trials →Access and Reimbursement
Ketamine/esketamine access; no state-regulated classical psychedelic pathwayPractical access today is lawful ketamine and FDA-approved esketamine within ordinary psychiatric practice. Nothing in the reviewed Tennessee sources suggests a live psilocybin, MDMA or natural-medicine therapeutic pathway outside research. Because Tennessee has not built a separate psychedelic access regime, patient-access questions are mostly conventional ones: clinician availability, payer tolerance for esketamine, and the usual self-pay caveats around off-label ketamine.
Research signal
Not ReviewedThe clearest verified local research signal is Vanderbilt. In 2024 Vanderbilt University Medical Center publicised new ketamine research aimed at extending relief from depression, which shows active academic engagement with rapid-acting antidepressant science in the state.
Ketamine / esketamine
AvailablePractical access today is lawful ketamine and FDA-approved esketamine within ordinary psychiatric practice. Nothing in the reviewed Tennessee sources suggests a live psilocybin, MDMA or natural-medicine therapeutic pathway outside research.
No state service model
Not AvailableNo state-regulated psilocybin, MDMA or natural-medicine service model is verified for Tennessee.
Classical psychedelics
Not AvailableThe strongest policy evidence gathered here is negative rather than positive: Tennessee’s current rules continue to list psilocybin and psilocin in Schedule I. No primary-source bill or agency pathway reviewed here suggested a shift towards legal therapeutic psilocybin or MDMA access.
Reimbursement / payment
LimitedTennessee has state-specific Medicaid or payer material relevant to esketamine, but current plan criteria should be rechecked before relying on coverage details.
Policy and Access Timeline
State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.
1 Apr 2026
ActiveAgency GuidanceTennessee rule filing continues to list psilocybin and psilocin in Schedule I
Tennessee rule filing continues to list psilocybin and psilocin in Schedule I.
TennesseeTennessee controlled-substances rules→1 Jan 2023
ActiveAgency GuidanceTennessee publishes revised controlled-substances rules listing psilocybin in Schedule I
Tennessee publishes revised controlled-substances rules listing psilocybin in Schedule I.
TennesseeTennessee controlled-substances rules→1 Jan 2015
ActiveAgency GuidanceTennessee Public Chapter 302 includes psilocybin and psilocin in statutory schedule text
Tennessee Public Chapter 302 includes psilocybin and psilocin in statutory schedule text.
TennesseePublic Chapter 302→
Regulatory Status
Tennessee remains a standard controlled-substances jurisdiction for classical psychedelics. Current Tennessee rules list psilocybin and psilocin in Schedule I, and the reviewed materials did not identify an enacted psychedelic-specific access pathway, state service model or local deprioritisation framework. The state’s scheduling system is maintained through Department of Mental Health and Substance Abuse Services rule filings that compare state schedules with federal schedules. That indicates administrative upkeep, not reform. On present evidence, Tennessee should be treated as a prohibition state for classical psychedelics.
Medical Access Summary
Practical access today is lawful ketamine and FDA-approved esketamine within ordinary psychiatric practice. Nothing in the reviewed Tennessee sources suggests a live psilocybin, MDMA or natural-medicine therapeutic pathway outside research.###
Because Tennessee has not built a separate psychedelic access regime, patient-access questions are mostly conventional ones: clinician availability, payer tolerance for esketamine, and the usual self-pay caveats around off-label ketamine. This page should not imply that Tennessee offers any state-recognised psychedelic services market.###
Local Research Map
Verified Blossom records with coordinates in Tennessee, including trial sites, physical stakeholders and events.
Policy and Access Context
The strongest policy evidence gathered here is negative rather than positive: Tennessee’s current rules continue to list psilocybin and psilocin in Schedule I. No primary-source bill or agency pathway reviewed here suggested a shift towards legal therapeutic psilocybin or MDMA access.###
For access researchers, this means Tennessee currently matters more as a conventional medical and academic state than as a reform state. If change comes, it is more likely to come first through federal product approvals or research than through Tennessee-led state policy innovation on current evidence.###
Research Focus
The clearest verified local research signal is Vanderbilt. In 2024 Vanderbilt University Medical Center publicised new ketamine research aimed at extending relief from depression, which shows active academic engagement with rapid-acting antidepressant science in the state.###
What is not yet verified in the material reviewed is a major Tennessee classical-psychedelic trial platform. Tennessee therefore reads as a ketamine-relevant academic state, but not a confirmed psilocybin/MDMA research hub.###
Implementation Context
Since there is no psychedelic-specific statute to implement, Tennessee has no verified framework for service centres, facilitator training, advisory boards or psychedelic provider licensing. The implementation architecture that does exist is ordinary controlled-substances rulemaking through the state’s mental-health/substance-use agency.###
For real-world access, the operational issues are therefore mainstream ones: hospital or clinic willingness to run esketamine under REMS, and clinician willingness to offer ketamine within conventional standards of care.###
Ecosystem Context
The verified ecosystem is anchored by Vanderbilt’s research reputation rather than by an identifiable statewide psychedelic-policy or community-services network. For now, Tennessee’s psychic centre of gravity in this field appears to be academic mood-disorder research, not reform politics.###
This makes Tennessee noteworthy but not market-defining. It is present on the map through academic ketamine work, yet still lacks the policy and implementation features that would create distinctive state-level psychedelic access.###
Key Milestones
Future Outlook
In the next 12 to 24 months, Tennessee’s likely trajectory is incremental clinical growth in ketamine/esketamine and continued academic work at institutions such as Vanderbilt, rather than state-led psychedelic implementation.###
Any meaningful shift for classical psychedelics would probably depend on federal product approval, trial expansion or a new state bill that was not visible in the reviewed materials. Until such a change appears, Tennessee remains a low-policy-momentum jurisdiction.###
Sources and Verification
Last updated 18 May 2026. Source links are drawn from citation annotations in the subnational report.
State-Linked Stakeholders
Organisations with verified physical locations or jurisdiction-level coverage in Tennessee.
Clinical Trials
Trial records with verified sites in Tennessee.